The prognostic value of choline PET/CT in the initial assessment of HCC pts

Dr Hugo Couvert, resident in gastroenterology at the Jules Bordet Institute presented the outcomes of a retrospective study investigating the prognostic utility of choline PET/CT in comparison to MRI and FDG PET/CT in patients with treatment-naïve HCC, focusing on correlations with OS. A cohort of HCC patients underwent imaging with all three modalities prior to therapy initiation. Prognostic performance was assessed through survival analysis and stratification by imaging findings.
In treatment-naïve HCC, choline PET/CT tumour volume and uptake seem to offer no added prognostic benefit over MRI or FDG PET/CT. Although choline PET/CT correlates well with MRI-derived tumour volumes, its routine clinical use is not supported. It may serve as an alternative when MRI is unavailable.